Literature DB >> 1057449

Growth rate of pulmonary metastases in human sarcomas.

P R Band, C Kocandrle.   

Abstract

The growth rate of spherical pulmonary metastases was studied in 15 patients with osseous and soft tissue sarcoma. The median volume doubling time (Dt) was 25 days. The time from diagnosis of the primary tumor to occurrence of pulmonary metastases correlated directly with the length of Dt. No correlation between Dt and tumor histology was observed. The effect of therapy on the tumor growth curve was studied in 1 patient. The therapeutic implications derived from the quantitative evaluation of tumor growth rate are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1057449     DOI: 10.1002/1097-0142(197508)36:2<471::aid-cncr2820360225>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Rapidly growing intrathoracic extraskeletal Ewing's sarcoma.

Authors:  Yoshio Tsunezuka; Takahiro Furusawa; Tsuyoshi Yachi; Hiroshi Kurumaya
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-15

2.  Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Takao Matsubara; Kunihiro Asanuma; Astumasa Uchida; Akihiro Sudo
Journal:  Clin Exp Metastasis       Date:  2011-07-30       Impact factor: 5.150

Review 3.  Small cell anaplastic carcinoma of the lung. A review of growth characteristics and implications for chemotherapy.

Authors:  B A Brigham
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.

Authors:  H C A Graat; M A Witlox; F H E Schagen; G J L Kaspers; M N Helder; J Bras; G R Schaap; W R Gerritsen; P I J M Wuisman; V W van Beusechem
Journal:  Br J Cancer       Date:  2006-05-30       Impact factor: 7.640

5.  Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).

Authors:  Karen L Reckamp; Paul H Frankel; Nora Ruel; Philip C Mack; Barbara J Gitlitz; Tianhong Li; Marianna Koczywas; Shirish M Gadgeel; Mihaela C Cristea; Chandra P Belani; Edward M Newman; David R Gandara; Primo N Lara
Journal:  Front Oncol       Date:  2019-03-11       Impact factor: 6.244

6.  Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma.

Authors:  C Blomqvist; T Wiklund; M Tarkkanen; I Elomaa; M Virolainen
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.